{"id":"NCT04599465","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","officialTitle":"A Phase 3b Open-label Study to Assess the Effect of Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) on Glucose Tolerance in Cystic Fibrosis Subjects With Abnormal Glucose Metabolism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-15","primaryCompletion":"2022-07-14","completion":"2022-07-14","firstPosted":"2020-10-22","resultsPosted":"2023-08-03","lastUpdate":"2023-08-03"},"enrollment":69,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function mutation (F/MF genotypes), with abnormal glucose metabolism.","primaryOutcome":{"measure":"Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48","timeFrame":"Baseline, Week 36 and 48","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":-35,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":41,"countries":["Australia","Belgium","Czechia","France","Italy","Netherlands","Spain"]},"refs":{"pmids":["40788823"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":69},"commonTop":["COVID-19","Pyrexia","Headache","Nasopharyngitis","Diarrhoea"]}}